Clinical Trials › NCT06138132
RecruitingPhase 1
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis
Sponsored by Stanford University
Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov 12
Target enrollment
1
U.S. states
Apr 2024
Start date
Jun 2027
Expected completion
Interventions / Treatments
KYV-101 anti-CD19 CAR-T cell therapyStandard lymphodepletion regimen
Conditions studied
Multiple SclerosisMultiple Sclerosis, Primary ProgressiveMultiple Sclerosis, Secondary Progressive
Where this trial is running (1 site)
California1 site
Palo Alto
Participating MS centers on MS Buddy (1)
Stanford MS & Neuroimmunology Clinic
Palo Alto, CA
Palo Alto, CA
MS centers in California
Compare treatment centers near a trial site by center type, providers and trials.
View California centersMore Phase 1 trials
Browse all Phase 1 MS trialsThe app
Check out the MS Buddy app
Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.